Kevan C. Herold, M.D.
Type 1 Diabetes TrialNet Principal Investigator
Yale University School of Medicine
- Professor of Immunobiology and Medicine, Yale University School of Medicine
Dr. Herold is well known for his work in the field of type 1 diabetes research. He was part of the team that was the first to report use of anti-CD3 monoclonal antibody (a treatment now in development). Much of his recent work pertains to the mechanisms of immune regulation by anti-CD3 mAb in patients. He is developing new immunologic and metabolic approaches to prevent the progression of type 1 diabetes. His work bridges the fields of basic immunology, clinical trials and clinical medicine.
- Autoimmune diseases and diabetes
- Beta cell growth
- Induction of immunologic tolerance to autoimmunity
Dr. Herold is a graduate of Jefferson Medical College, of Philadelphia. He performed his internship and residency in Internal Medicine at Temple University Hospital, in Philadelphia, and two fellowships, one in endocrinology and one in immunology, at the University of Chicago.
Dr. Herold is the recipient of the Robert Levine and Mary Tyler Moore award in Translational Diabetes Research from the Juvenile Diabetes Research Foundation (JDRF). He has also received a number of awards from the National Institutes of Health and JDRF.
To schedule an interview
Please contact Laurie Feldman at (203)737-2760 or email@example.com.